Surgical management of obesity in patients with morbid obesity and nonalcoholic fatty liver disease

Clinics in Liver Disease

Volumn 18, Issue 1, 2014, Pages 129-146

  Dixon, John B ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Diabetes; Gastric; Hypertension; Malabsorption; Metabolic; Mortality; Surgery; Weight loss

Indexed keywords

BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; DECOMPENSATED LIVER CIRRHOSIS; GASTROPLASTY; HUMAN; LAPAROSCOPIC ADJUSTABLE GASTRIC BAND; LAPAROSCOPIC SURGERY; LIVER BIOPSY; LIVER FAILURE; MORBID OBESITY; MORBIDITY; MORTALITY; NONALCOHOLIC FATTY LIVER; REVIEW; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; WEIGHT REDUCTION;

DIABETES; GASTRIC; HYPERTENSION; MALABSORPTION; METABOLIC; MORTALITY; SURGERY; WEIGHT LOSS;

BARIATRIC SURGERY; FATTY LIVER; HUMANS; LIFE STYLE; LIVER; OBESITY, MORBID; WEIGHT LOSS;

EID: 84888057737     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2013.09.011     Document Type: Review

References (94)

1. Wagner E.H. Chronic disease management: what will it take to improve care for chronic illness?. Eff Clin Pract 1998, 1(1):2-4.
2. Schwartz M.W., Woods S.C., Seeley R.J., et al. Is the energy homeostasis system inherently biased toward weight gain?. Diabetes 2003, 52(2):232-238.
3. Rosenbaum M., Goldsmith R., Bloomfield D., et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. JClin Invest 2005, 115(12):3579-3586.
4. Rosenbaum M., Kissileff H.R., Mayer L.E., et al. Energy intake in weight-reduced humans. Brain Res 2010, 1350:95-102.
5. Chan E.W., He Y., Chui C.S., et al. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev 2013, 14(5):383-392.
6. Cameron F., Whiteside G., McKeage K. Phentermine and topiramate extended release (Qsymia): first global approval. Drugs 2012, 72(15):2033-2042.
7. Padwal R., Li S.K., Lau D.C. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003, 27(12):1437-1446.
8. Gadde K.M., Allison D.B., Ryan D.H., et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377(9774):1341-1352.
9. Smith S.R., Weissman N.J., Anderson C.M., et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. NEngl J Med 2010, 363(3):245-256.
10. Dixon J.B., Straznicky N.E., Lambert E.A., et al. Surgical approaches to the treatment of obesity. Nat Rev Gastroenterol Hepatol 2011, 8:429-437.
11. Buchwald H., Oien D.M. Metabolic/bariatric surgery worldwide 2008. Obes Surg 2009, 19(12):1605-1611.
12. Buchwald H., Oien D.M. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013, 23(4):427-436.
13. NHMRC National Health and Medical Research Council: clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia 2013, National Health and Medical Research Council, Melbourne (Australia).
14. Dixon J.B., Zimmet P., Alberti K.G., et al. Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med 2011, 28(6):628-642.
15. Magkos F., Su X., Bradley D., et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 2012, 142:1444-1446.e2.
16. Lim E.L., Hollingsworth K.G., Aribisala B.S., et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011, 54(10):2506-2514.
17. Dixon J.B., Straznicky N.E., Lambert E.A., et al. Laparoscopic adjustable gastric banding and other devices for the management of obesity. Circulation 2012, 126(6):774-785.
18. Odstrcil E.A., Martinez J.G., Santa Ana C.A., et al. The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. Am J Clin Nutr 2010, 92(4):704-713.
19. Ionut V., Burch M., Youdim A., et al. Gastrointestinal hormones and bariatric surgery induced weight loss. Obesity (Silver Spring) 2013, 21:1093-1103.
20. Pontiroli A.E., Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. a systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg 2011, 253(3):484-487.
21. Sjostrom L., Narbro K., Sjostrom C.D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. NEngl J Med 2007, 357(8):741-752.
22. Adams T.D., Gress R.E., Smith S.C., et al. Long-term mortality after gastric bypass surgery. NEngl J Med 2007, 357(8):753-761.
23. Mingrone G., Panunzi S., De Gaetano A., et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. NEngl J Med 2012, 366:1577-1585.
24. Schauer P.R., Kashyap S.R., Wolski K., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. NEngl J Med 2012, 366:1567-1576.
25. Dixon J.B., O'Brien P.E., Playfair J., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008, 299(3):316-323.
26. Ikramuddin S., Korner J., Lee W.J., et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013, 309(21):2240-2249.
27. O'Brien P.E., Dixon J.B., Laurie C., et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 2006, 144(9):625-633.
28. Sjoström L. Review of the key results from the Swedish Obese Subjects (SOS) trial: a prospective controlled intervention study of bariatric surgery. JIntern Med 2013, 273:219-234.
29. Picot J., Jones J., Colquitt J.L., et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009, 13(41):1-190. 215-357, iii-iv.
30. Finkelstein E.A., Allaire B.T., Burgess S.M., et al. Financial implications of coverage for laparoscopic adjustable gastric banding. Surg Obes Relat Dis 2011, 7(3):295-303.
31. Keating C.L., Dixon J.B., Moodie M.L., et al. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diabetes Care 2009, 32(4):567-574.
32. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121(1):91-100.
33. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55(6):2005-2023.
34. Dixon J.B., Bhathal P.S., Hughes N.R., et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004, 39(6):1647-1654.
35. Mathurin P., Hollebecque A., Arnalsteen L., et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009, 137(2):532-540.
36. Chavez-Tapia N.C., Tellez-Avila F.I., Barrientos-Gutierrez T., et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010, (1). CD007340.
37. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129(1):113-121.
38. Burza M.A., Romeo S., Kotronen A., et al. Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) Study. PLoS One 2013, 8(3):e60495.
39. Treeprasertsuk S., Bjornsson E., Enders F., et al. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol 2013, 19(8):1219-1229.
40. Arun J., Jhala N., Lazenby A.J., et al. Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes Surg 2007, 17(2):155-161.
41. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128(7):1898-1906.
42. Meinhardt N.G., Souto K.E., Ulbrich-Kulczynski J.M., et al. Hepatic outcomes after jejunoileal bypass: is there a publication bias?. Obes Surg 2006, 16(9):1171-1178.
43. Silverman E.M., Sapala J.A., Appelman H.D. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995, 104(1):23-31.
44. Liu X., Lazenby A.J., Clements R.H., et al. Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg 2007, 17(4):486-492.
45. Vargas V., Allende H., Lecube A., et al. Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients. World J Hepatol 2012, 4(12):382-388.
46. Mathurin P., Gonzalez F., Kerdraon O., et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 2006, 130(6):1617-1624.
47. DeWind L.T., Payne J.H. Intestinal bypass surgery for morbid obesity. Long-term results. JAMA 1976, 236(20):2298-2301.
48. Rucker R.D., Horstmann J., Schneider P.D., et al. Comparisons between jejunoileal and gastric bypass operations for morbid obesity. Surgery 1982, 92(2):241-249.
49. Hocking M.P., Davis G.L., Franzini D.A., et al. Long-term consequences after jejunoileal bypass for morbid obesity. Dig Dis Sci 1998, 43(11):2493-2499.
50. O'Leary J.P. Hepatic complications of jejunoileal bypass. Semin Liver Dis 1983, 3(3):203-215.
51. Antal S.C. Prevention and reversal of liver damage following biliopancreatic diversion for obesity. Obes Surg 1994, 4(3):285-290.
52. Castillo J., Fabrega E., Escalante C.F., et al. Liver transplantation in a case of steatohepatitis and subacute hepatic failure after biliopancreatic diversion for morbid obesity. Obes Surg 2001, 11(5):640-642.
53. Papadia F., Marinari G.M., Camerini G., et al. Short-term liver function after biliopancreatic diversion. Obes Surg 2003, 13(5):752-755.
54. Kral J.G., Thung S.N., Biron S., et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004, 135(1):48-58.
55. Keshishian A., Zahriya K., Willes E.B. Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months. Obes Surg 2005, 15(10):1418-1423.
56. Andersen T., Larsen U. Dietary outcome in obese patients treated with a gastroplasty program. Am J Clin Nutr 1989, 50(6):1328-1340.
57. Andersen T. Liver and gallbladder disease before and after very-low-calorie diets. Am J Clin Nutr 1992, 56(1 Suppl):235S-239S.
58. Andersen T., Gluud C., Franzmann M.B., et al. Hepatic effects of dietary weight loss in morbidly obese subjects. JHepatol 1991, 12(2):224-229.
59. Mosko J.D., Nguyen G.C. Increased perioperative mortality following bariatric surgeryamong patients with cirrhosis. Clin Gastroenterol Hepatol 2011, 9(10):897-901.
60. Shimizu H., Phuong V., Maia M., et al. Bariatric surgery in patients with liver cirrhosis. Surg Obes Relat Dis 2013, 9(1):1-6.
61. Cobb W.S., Heniford B.T., Burns J.M., et al. Cirrhosis is not a contraindication to laparoscopic surgery. Surg Endosc 2005, 19(3):418-423.
62. Dallal R.M., Mattar S.G., Lord J.L., et al. Results of laparoscopic gastric bypass in patients with cirrhosis. Obes Surg 2004, 14(1):47-53.
63. Peng L., Wang J., Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev 2011, (6). CD003619.
64. Serrot F.J., Dorman R.B., Miller C.J., et al. Comparative effectiveness of bariatric surgery and nonsurgical therapy in adults with type 2 diabetes mellitus and body mass index <35 kg/m(2). Surgery 2011, 150(4):684-691.
65. Arterburn D.E., Bogart A., Sherwood N.E., et al. Amultisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013, 23:93-102.
66. NIH Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992, 55(2 Suppl):615S-619S.
67. NICE Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children 2006, National Institute for Health and Clinical Excellence, London.
68. Fried M., Hainer V., Basdevant A., et al. Inter-disciplinary European guidelines on surgery of severe obesity. Int J Obes (Lond) 2007, 31(4):569-577.
69. Logue J., Thompson L., Romanes F., et al. Management of obesity: summary of SIGN guideline. BMJ 2010, 340:c154.
70. Brethauer S.A., Hammel J.P., Schauer P.R. Systematic review of sleeve gastrectomy as staging and primary bariatric procedure. Surg Obes Relat Dis 2009, 5(4):469-475.
71. O'Brien P.E., McPhail T., Chaston T.B., et al. Systematic review of medium-term weight loss after bariatric operations. Obes Surg 2006, 16(8):1032-1040.
72. Fischer L., Hildebrandt C., Bruckner T., et al. Excessive weight loss after sleeve gastrectomy: a systematic review. Obes Surg 2012, 22(5):721-731.
73. Chapman A., Kiroff G., Game P., et al. Laparoscopic adjustable gastric banding in the treatment of obesity: a systematic review. Surgery 2004, 135:326-351.
74. Buchwald H., Estok R., Fahrbach K., et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007, 142(4):621-632.
75. Flum D.R., Belle S.H., King W.C., et al. Perioperative safety in the longitudinal assessment of bariatric surgery. NEngl J Med 2009, 361(5):445-454.
76. DeMaria E.J., Pate V., Warthen M., et al. Baseline data from American Society for Metabolic and Bariatric Surgery-designated Bariatric Surgery Centers of Excellence using the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis 2010, 6(4):347-355.
77. O'Brien P.E., Macdonald L., Anderson M., et al. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg 2013, 257(1):87-94.
78. Mechanick J.I., Youdim A., Jones D.B., et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring) 2013, 21(Suppl 1):S1-S27.
79. Ranlov I., Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 1990, 47(4):208-214.
80. Luyckx F.H., Desaive C., Thiry A., et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998, 22(3):222-226.
81. Clark J.M., Alkhuraishi A.R., Solga S.F., et al. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 2005, 13(7):1180-1186.
82. Mattar S.G., Velcu L.M., Rabinovitz M., et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005, 242(4):610-617. [discussion: 618-20].
83. Mottin C.C., Moretto M., Padoin A.V., et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obes Surg 2005, 15(6):788-793.
84. Stratopoulos C., Papakonstantinou A., Terzis I., et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 2005, 15(8):1154-1160.
85. Barker K.B., Palekar N.A., Bowers S.P., et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 2006, 101(2):368-373.
86. Csendes A., Smok G., Burgos A.M. Histological findings in the liver before and after gastric bypass. Obes Surg 2006, 16(5):607-611.
87. de Almeida S.R., Rocha P.R., Sanches M.D., et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 2006, 16(3):270-278.
88. Dixon J.B., Bhathal P.S., O'Brien P.E. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 2006, 16(10):1278-1286.
89. Klein S., Mittendorfer B., Eagon J.C., et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 2006, 130(6):1564-1572.
90. Furuya C.K., de Oliveira C.P., de Mello E.S., et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. JGastroenterol Hepatol 2007, 22(4):510-514.
91. Bell L.N., Temm C.J., Saxena R., et al. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg 2010, 251(6):1041-1048.
92. Weiner R.A. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 2010, 28(1):274-279.
93. Tai C.M., Huang C.K., Hwang J.C., et al. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg 2012, 22(7):1016-1021.
94. Moretto M., Kupski C., da Silva V.D., et al. Effect of bariatric surgery on liver fibrosis. Obes Surg 2012, 22(7):1044-1049.